A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
Evidence dashboardStudies since 2022Updated Jul 31, 2026
EloralintideClinical Trials.
A source-linked view of every Eloralintide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 20
- Recruiting
- 11
- Completed
- 6
- Terminated
- 0
- Results posted
- 1
- Average enrollment
- 460
- Countries
- 25
- Highest phase
- Phase 3
Largest indexed study
1,980 participants · NCT07321886 →Developer / research origin
Eli Lilly
Evidence summary
Activity is not efficacy.
Eloralintide appears in 20 indexed studies: 11 recruiting, 6 completed and 1 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Eloralintide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Active, not recruiting
367
2026-07
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
200
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
1,035
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 3
Recruiting
1,980
2026-07
Showing 6 of 14 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Completed
263
2026-06
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Eli Lilly · Overweight · Obesity
Phase 1
Completed
188
2026-01
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Completed
128
2026-01
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Completed
30
2025-11
A Study of LY3841136 in Overweight and Obese Participants
Eli Lilly · Obesity · Overweight
Phase 1
Completed
96
2025-10
A Study of LY3841136 in Healthy and Overweight Participants
Eli Lilly · Obesity · Healthy
Phase 1
Completed
148
2024-04
No studies in this snapshot.
Full study index
Search Eloralintide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
20 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41207310 ↗Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 6;406(10520):2631-2643. doi: 10.1016/S0140-6736(25)02155-5. Epub 2025 Nov 6.Linked from NCT06230523PMID 41109426 ↗Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, Long A, Allen D, O'Farrell L, Bowen B, Pratt E, Tidemann-Miller B, Tham LS, Ibriga H, Alsina-Fernandez J, Mather KJ, Haupt A, Bhattachar SN. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271. doi: 10.1016/j.molmet.2025.102271. Epub 2025 Oct 16.Linked from NCT05295940
Related pages
Keep researching Eloralintide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.